These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1060 related articles for article (PubMed ID: 34706189)
1. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE; N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189 [TBL] [Abstract][Full Text] [Related]
2. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE; JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520 [TBL] [Abstract][Full Text] [Related]
4. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Satram S; Ghafoori P; Reyes CM; Keeley TJH; Birch HJ; Brintziki D; Aldinger M; Alexander E; Lopuski A; Sarkis EH; Gupta A; Shapiro AE; Powers JH J Patient Rep Outcomes; 2023 Sep; 7(1):92. PubMed ID: 37702920 [TBL] [Abstract][Full Text] [Related]
5. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression. Lokhandwala T; Acharya M; Farrelly E; Coutinho AD; Bell CF; Svedsater H J Manag Care Spec Pharm; 2022 Nov; 28(11):1261-1271. PubMed ID: 36282931 [No Abstract] [Full Text] [Related]
6. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD N Engl J Med; 2021 Mar; 384(10):905-914. PubMed ID: 33356051 [TBL] [Abstract][Full Text] [Related]
7. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701 [TBL] [Abstract][Full Text] [Related]
8. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778 [TBL] [Abstract][Full Text] [Related]
9. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM; N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. Chen P; Nirula A; Heller B; Gottlieb RL; Boscia J; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Adams AC; Van Naarden J; Custer KL; Shen L; Durante M; Oakley G; Schade AE; Sabo J; Patel DR; Klekotka P; Skovronsky DM; N Engl J Med; 2021 Jan; 384(3):229-237. PubMed ID: 33113295 [TBL] [Abstract][Full Text] [Related]
12. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383 [TBL] [Abstract][Full Text] [Related]
13. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM; JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073 [TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. Bell CF; Gibbons DC; Drysdale M; Birch HJ; Lloyd EJ; Patel V; Carpenter C; Carlson K; Calay ES; Puranik A; Wagner TE; O'Horo JC; Razonable RR PLoS One; 2024; 19(7):e0304822. PubMed ID: 39012863 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
16. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA; N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574 [TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. Rosas IO; Bräu N; Waters M; Go RC; Hunter BD; Bhagani S; Skiest D; Aziz MS; Cooper N; Douglas IS; Savic S; Youngstein T; Del Sorbo L; Cubillo Gracian A; De La Zerda DJ; Ustianowski A; Bao M; Dimonaco S; Graham E; Matharu B; Spotswood H; Tsai L; Malhotra A N Engl J Med; 2021 Apr; 384(16):1503-1516. PubMed ID: 33631066 [TBL] [Abstract][Full Text] [Related]
20. [Sotrovimab in controlling SARS-CoV-2 infection]. Płusa T Pol Merkur Lekarski; 2022 Feb; 50(295):48-50. PubMed ID: 35278299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]